Featured Blog Posts – March 2016 Archive (5)
Staff PPMD is Initial Partner in OnPAR — Online Partnership to Accelerate Research
The National Institutes of Health (NIH) is one of the biggest funders of medical research in the US, and projects it has funded have touched almost every Duchenne therapeutic in development now in some way. In FY2016, the NIH is…
ContinueAdded by Abby Bronson on March 24, 2016 at 9:30am — No Comments
Staff FDA Releases New Date for Eteplirsen Ad Comm
At long last we have received information regarding the rescheduled Advisory Committee for Sarepta (eteplirsen). The Ad Comm will take place on Monday, April 25 at the College…
ContinueAdded by PPMD on March 10, 2016 at 9:00am — No Comments
Staff How You Can Participate in Upcoming FDA Advisory Committee Meetings
Added by PPMD on March 10, 2016 at 9:00am — No Comments
Staff Gene Therapy Today: Notes from PPMD’s Duchenne Gene Therapy Forum
Gene therapy.
Those two words have been tossed around for some time, starting in the late 1990s when several gene therapy trials started, but ended with fatal results. Now, when the field has learned a lot from those initial results and with optimized technologies, we come back to gene…
ContinueAdded by Abby Bronson on March 8, 2016 at 12:00pm — 4 Comments
Staff PPMD Launches the Every Single [One] Tour
For 22 years, PPMD has brought together families with leading experts, care providers, and industry partners through our Annual Connect Conference,…
ContinueLatest Featured Blog Posts
- PPMD Designates UC Davis a Certified Duchenne Care Center
- PPMD Working with FDA to Plan Landmark Pediatric Advisory Committee Meeting to Improve Clinical Trial Experience
- PPMD's Duchenne Drug Development Roundtable Meeting Series, Part 3: Clinical Trial Readiness from the Viewpoint of Clinicians and Infrastructure
- ACTION ALERT: Make Your Voice Heard on New Healthcare Proposal
- PPMD's Duchenne Drug Development Roundtable Meeting Series, Part 2: Optimizing Clinical Trials
- PPMD Designates Ann & Robert H. Lurie Children's Hospital of Chicago a Certified Duchenne Care Center
- Marathon Pharmaceuticals Pauses Commercialization of EMFLAZA™ (deflazacort)
Most Popular Featured Blog Posts
- FDA Grants Accelerated Approval to First Drug for Duchenne Muscular Dystrophy
- Deflazacort Approved in the U.S. for Duchenne
- A Historic Day for Duchenne
- Early morning calls
- Action ALERT: Urge Congress to Vote YES on 21st Century Cures Act
- PPMD Announces Gene Therapy Forum
- What You Need to Know about Duchenne & Viral Gastroenteritis (That Horrible Stomach Bug!)
Featured Monthly Archives
2017
2016
- December (1)
- November (1)
- October (3)
- September (2)
- August (2)
- July (2)
- June (1)
- May (2)
- April (2)
- March (6)
- February (4)
- January (3)
2015
- December (3)
- November (3)
- October (4)
- September (5)
- August (5)
- July (6)
- June (3)
- May (2)
- April (4)
- March (3)
- February (5)
- January (7)
2014
- December (2)
- November (3)
- October (5)
- September (3)
- August (1)
- July (2)
- June (1)
- May (3)
- April (3)
- March (1)
- February (1)
- January (1)
2013
- December (5)
- November (4)
- October (6)
- September (5)
- August (3)
- July (5)
- June (3)
- May (6)
- April (3)
- March (6)
- February (7)
- January (2)
2012
- December (3)
- November (5)
- October (12)
- September (11)
- August (8)
- July (4)
- June (5)
- May (5)
- April (5)
- March (8)
- February (6)
- January (5)
2011
- December (5)
- November (11)
- October (9)
- September (6)
- August (3)
- July (1)
- June (3)
- May (2)
- April (6)
- March (3)
- February (4)
- January (4)
2010
- December (4)
- November (2)
- October (2)
- September (4)
- August (3)
- July (3)
- June (3)
- May (3)
- April (4)
- February (1)
- January (6)
2009
- December (5)
- November (7)
- October (1)
- September (3)
- August (5)
- July (2)
- May (2)
- April (2)
- March (4)
- February (3)
- January (1)
2008
© 2019 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
